FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol OUESTCOR PHARMACEUTICALS INC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Fares James Lawrence</u>					QSC]							X	X Director			10% Owr	ier	
(Last) (First) (Middle)			_[X	Officer (give title below)			Other (specify below)			
3260 WHIPPLE ROAD					3. Date of Earliest Transaction (Month/Day/Year) 03/23/2006								1	Presiden	it & C	EO		
(Street)	Street) UNION CITY CA 94587		94587		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)													Form filed	а ву моге	tnan O	ne Reportin	g Person	
			Table I - Non-	Deriv	ative	Securi	ties Acqı	uired,	Disp	osed of,	or Bene	ficially O	wned					
			2. Transaction Date (Month/Day/Year)		Execur) if any	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Disposed Of				5. Amount of Securities Beneficially Following R Transaction	Owned Reported	6. Own Form: I (D) or I (I) (Inst	Direct Ir ndirect B r. 4) O	7. Nature of ndirect Beneficial Ownership Instr. 4)		
									v	Amount	(A) or (D)	Price	(Instr. 3 and			"	130.4)	
			Table II - D (e							sed of, or			ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative		3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned		10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Security			Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)		(I) (Instr. 4)		
Stock Option (Right to Buy) ⁽¹⁾	\$0.48	03/23/2006		D			125,000 ⁽³⁾	(2	2)	10/16/2015	Common Stock	125,000	\$0	\$0		D		
Stock Option (Right to Buy) ⁽¹⁾	\$1.43	03/23/2006		A		125,000		(2	2)	03/22/2016	Common Stock	125,000	\$0	0		D		

Explanation of Responses:

- 1. Incentive stock options granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan.
- 2. Options vest monthly over 48 months from the date of grant. The options have a twelve month cliff, whereby no options vest until after the twelfth month from the date of grant.
- 3. Options were rescinded.

/s/ James L. Fares 03/27/2006

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.